AAVantgarde Bio

AAVantgarde Bio is a clinical-stage biotechnology company headquartered in Milan, Italy, developing next-generation adeno-associated virus (AAV) gene therapies for inherited retinal diseases with high unmet need. Founded in 2021 by Prof. Alberto Auricchio, the company has built two proprietary vector platforms — dual hybrid and dual intein — that overcome the DNA cargo capacity limit of a single AAV vector by splitting a large expression cassette across two AAV8 vectors that recombine inside the target cell. Its lead programs are AAVB-081 for retinitis pigmentosa due to Usher syndrome type 1B (LUCE-1 Phase 1/2, the first dual AAV gene therapy tested clinically in an ocular indication) and AAVB-039 for ABCA4-associated Stargardt disease (CELESTE Phase 1/2), which holds FDA Fast Track and Orphan Drug designation. The company raised a EUR 61 million Series A and closed a USD 141 million Series B. AAVantgarde publishes no public API, developer program or machine-readable contract; this profile records what its public web surface actually serves.

AAVantgarde Bio is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Gene Therapy, Life Sciences, and Pharmaceuticals.

AAVantgarde Bio’s developer surface includes engineering blog and 10 more developer resources.

🌐 Visit website 📡 Source on GitHub
11.6/100 emerging ▬ flat Agent 11/100 agent aware Front door AI 1/6 silent Full breakdown ↓
scored 2026-09-25 · rubric v0.23.0
0 APIs
CompanyBiotechnologyGene TherapyLife SciencesPharmaceuticalsClinical TrialsOphthalmologyRare DiseaseHealthcareItaly

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-09-25 · rubric v0.23.0
Composite quality — 11.6/100 · emerging
Contract Quality 0.0 / 21
Developer Ergonomics 0.4 / 17
Access Clarity 1.8 / 17
Operational Transparency 0.0 / 11
Contract Governance 1.9 / 10
Discoverability 4.7 / 9
Regulatory Posture 3.2 / 15
Agent readiness — 11/100 · agent aware
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
Documented Reversibility 0 / 6
MCP Server 0 / 12
Machine-Readable Auth 10 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Delegated User Identity 6 / 6
Protected Resource Metadata 0 / 5
Registration Without a Human 0 / 6
Agentic Commerce Well-Known Document 0 / 5
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero: never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and several others — scorable at all.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. Every facet and dimension name above is a link: it opens that measurement's own page — what it means, the exact checks that feed it, how the whole catalog distributes on it, and the providers at the top of it. This rating is computed from github.com/api-evangelist/aavantgardebio: open an issue to ask a question, or submit a pull request to add artifacts. Submit an artifact on GitHub — free → Manage your own listing — the Influence plan, $499/mo →

Security Posture 2

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Aavantgardebio Domain Security

TLSv1.3 · HSTS · DMARC

SECURITY

Aavantgardebio Vulnerability Disclosure

Hackerone · security.txt · contact published

SECURITY

Resources

Agent Surfaces 2

MCP servers, agent skills, and machine-readable catalogs

WellKnown
WellKnown
 LLMsTxt
LLMsTxt

Design & Contract 1

Pagination, idempotency, versioning, errors, and events

Conformance
Conformance

Access & Security 3

Authentication, authorization, and security posture

VulnerabilityDisclosure
VulnerabilityDisclosure
 SecurityTxt
SecurityTxt
 DomainSecurity
DomainSecurity

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy
PrivacyPolicy

Company 4

The organization behind the API

Website
Website
 About
About
 Blog
Blog
 LinkedIn
LinkedIn

Source (apis.yml)

apis.yml Raw ↑ 
aid: aavantgardebio
name: AAVantgarde Bio
description: AAVantgarde Bio is a clinical-stage biotechnology company headquartered in Milan, Italy, developing next-generation
  adeno-associated virus (AAV) gene therapies for inherited retinal diseases with high unmet need. Founded in 2021 by Prof.
  Alberto Auricchio, the company has built two proprietary vector platforms — dual hybrid and dual intein — that overcome
  the DNA cargo capacity limit of a single AAV vector by splitting a large expression cassette across two AAV8 vectors that
  recombine inside the target cell. Its lead programs are AAVB-081 for retinitis pigmentosa due to Usher syndrome type 1B
  (LUCE-1 Phase 1/2, the first dual AAV gene therapy tested clinically in an ocular indication) and AAVB-039 for ABCA4-associated
  Stargardt disease (CELESTE Phase 1/2), which holds FDA Fast Track and Orphan Drug designation. The company raised a EUR
  61 million Series A and closed a USD 141 million Series B. AAVantgarde publishes no public API, developer program or machine-readable
  contract; this profile records what its public web surface actually serves.
url: https://raw.githubusercontent.com/api-evangelist/aavantgardebio/refs/heads/main/apis.yml
image: https://www.aavantgarde.com/assets/img/AavantgardeBio-logo.svg
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enrichment-pass-2026-09-05
specificationVersion: '0.20'
created: '2026-09-05'
modified: '2026-09-05'
tags:
- Company
- Biotechnology
- Gene Therapy
- Life Sciences
- Pharmaceuticals
- Clinical Trials
- Ophthalmology
- Rare Disease
- Healthcare
- Italy
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: VulnerabilityDisclosure
  url: security/aavantgardebio-vulnerability-disclosure.yml
- type: Website
  url: https://www.aavantgarde.com/en/
- type: About
  url: https://www.aavantgarde.com/en/about/
- type: Blog
  url: https://www.aavantgarde.com/en/news/
- type: PrivacyPolicy
  url: https://www.aavantgarde.com/en/privacy-notice/
- type: LinkedIn
  url: https://www.linkedin.com/company/aavantgarde-bio
- type: WellKnown
  url: well-known/aavantgardebio-well-known.yml
- type: SecurityTxt
  url: well-known/aavantgardebio-security.txt
- type: Conformance
  url: conformance/aavantgardebio-conformance.yml
- type: DomainSecurity
  url: security/aavantgardebio-domain-security.yml
- type: LLMsTxt
  url: llms/aavantgardebio-llms.txt
x-enrichment:
  date: '2026-09-05'
  status: minimal
  artifacts_added: 8
  pass: local-v3
x-coverage:
  state: none
  reason: not-a-software-company
  detail: AAVantgarde Bio is a clinical-stage gene therapy company whose product is an investigational AAV vector, not software
    — the corporate site has no developer section at all (nav is About / Innovation / Clinical Trials / For Patients / News
    / Careers / Contact), api., developer., docs., status. and trust. subdomains are all NXDOMAIN, there is no GitHub organization,
    and the only machine-readable documents the site serves are the OpenID discovery and JWKS files its Umbraco CMS emits
    for website-member sign-in.
  evidence:
  - url: https://www.aavantgarde.com/en/
    status: 200
  - url: https://www.aavantgarde.com/llms.txt
    status: 404
  - url: https://www.aavantgarde.com/.well-known/api-catalog
    status: 404
  - url: https://www.aavantgarde.com/.well-known/agent-card.json
    status: 404
  - url: https://www.aavantgarde.com/.well-known/openid-configuration
    status: 200
  - url: https://api.github.com/orgs/aavantgarde-bio
    status: 404
  checked: '2026-09-05'

Work with this as data

Every provider here is available over the APIs.io API and to AI agents over MCP.

MCP server

One button, every client — Claude, Cursor, VS Code and the rest.

https://apis.io/mcp

Tools for providers

9 MCP tools reach this
  • find_providersBrowse and filter every provider in the catalog.
  • get_provider_artifactsEvery artifact this provider publishes, grouped by type.
  • get_provider_operationsEvery operation across all of their OpenAPIs — one call instead of parsing every spec.
  • get_provider_toolsEvery MCP tool they ship, with the operation each wraps.
  • get_provider_evidenceHow each part of their score was established. Free — the basis for a claim should not sit behind it.
  • get_provider_ratingPRO — composite, band, trend and facet scores.
  • apis_io_searchSTART HERE — APIs, providers and tags for one query, each with its total.
  • resolveTurn a domain, URL or GitHub org into the provider it belongs to.
  • find_cohortsEvery scored population of providers in the catalog.
All 92 tools →

Call it yourself

curl for this page
This provider 
curl "https://apis.io/api/v1/providers/aavantgardebio"
All providers 
curl "https://apis.io/api/v1/providers?limit=25"
Every operation they expose 
curl "https://apis.io/api/v1/providers/aavantgardebio/operations?limit=25"
How their score was established 
curl "https://apis.io/api/v1/providers/aavantgardebio/evidence"

Discovery needs no key. Ratings and market analysis are Pro.

Get an API key

Free tier, no form to fill in. Signing in shares your email address with us — we store it to create your key and to recognise you if you sign in with another provider. See our Privacy Policy and Terms.

GitHub Google LinkedIn

A second provider on the same verified email joins the account you already have.